Thromboxane metabolite excretion is associated with serious vascular events in diabetes mellitus: a sub-study of the ASCEND trial
Autors principals: | Rocca, B, Buck, G, Petrucci, G, Parish, S, Pagliaccia, F, Baigent, C, Mafham, M, Bowman, L, Armitage, J, Patrono, C |
---|---|
Altres autors: | The ASCEND Study Collaborative Group |
Format: | Conference item |
Idioma: | English |
Publicat: |
Oxford University Press
2020
|
Ítems similars
-
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial
per: Petrucci, G, et al.
Publicat: (2024) -
Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
per: Parish, S, et al.
Publicat: (2023) -
Once daily low-dose aspirin reduces urinary thromboxane B2 effectively even at 12-24 hours from dosing in the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial
per: Aung, T, et al.
Publicat: (2017) -
Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
per: Sarah Parish, et al.
Publicat: (2023-03-01) -
Measurement of Thromboxane Biosynthesis in Health and Disease
per: Carlo Patrono, et al.
Publicat: (2019-10-01)